Maxim Group Downgrades TrovaGene (TROV) to Hold; Capital Raise Needed
Tweet
Share
E-mailGet Alerts TROV Hot Sheet
Price: $1.19 --0%
Rating Summary:
7 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 44
Rating Summary:
7 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 44
Join SI Premium – FREE
Maxim Group downgraded TrovaGene (NASDAQ: TROV) from Buy to Hold.
Analyst Jason Kolbert said the company needs to raise capital. Once raised it will be in a stronger position to transition to a therapeutics company focused on PCM-075.
For an analyst ratings summary and ratings history on TrovaGene click here. For more ratings news on TrovaGene click here.
Shares of TrovaGene closed at $0.68 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Downgrades Unite Group (UTG:LN) to Underweight
- Morgan Stanley Downgrades Peter Warren Automotive Holdings Ltd (PWR:AU) to Equalweight
- UBS Downgrades Alkane Resources (ALK:AU) to Neutral
Create E-mail Alert Related Categories
Analyst Comments, DowngradesRelated Entities
Maxim GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
